Verigan Tablet 200 mg

৳ 400.00

Veritas Pharmaceuticals Ltd.

Category:

Indications

Treatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which other influenza antiviral drugs are ineffective or not sufficiently effective).

Therapeutic Class

Anti-viral drugs

Description

Favipiravir is approved for manufacture and sale in Japan as an influenza antiviral. It selectively inhibits the RNA polymerase of the influenza virus, an enzyme required for viral replication once human host cells are infected. COVID-19 also uses this enzyme to replicate and is classified into the same type of single-stranded RNA virus as influenza; hence, it is believed that Favipiravir may be effective in treating COVID-19.

Favipiravir is only used when there is an outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are either not effective or insufficiently effective. Its production and distribution is at the discretion of Japan’s Health, Labor and Welfare Ministry, so has never been distributed in the market and is not available at hospitals and pharmacies in Japan or overseas.

Pharmacology

Favipiravir is a new antiviral drug against influenza. It is metabolized into favipiravir ribosyl triphosphate (favipiravir RTP) by an intracellular enzyme, and favipiravir RTP selectively inhibits RNA polymerase (RNA-dependent RNA polymerase) of the influenza virus, preventing replication of the influenza virus. It is a drug with a mechanism of action different from that of the existing influenza antiviral drugs and effective against all types and sub-types of human influenza A, B, and C viruses in vitro, showing a wide range of anti-viral activity against various influenza virus strains including avian and swine viruses.

Dosage & Administration

The usual adult dosage is 1600 mg of Favipiravir administered orally twice daily on Day 1, followed by 600 mg orally twice daily from Day 2 to Day 5 or as directed by physicians. The total treatment duration should be 5 days.

Interaction

This drug is only approved as an experimental drug and still a lot of studies is needed about it’s efficacy and also toxic reactions and drug interactions.

Contraindications

This drug is only approved as an experimental drug and still a lot of studies is needed about its efficacy and also toxic reactions and contraindications.

Side Effects

This drug is only approved as an experimental drug and still a lot of studies is needed about it’s efficacy and also toxic reactions and other side effects.

Pregnancy & Lactation

It needs to be used with great care and under tight controls because of a serious side effect that could cause fetal abnormalities if a pregnant woman took the drug. It’s potential for causing birth defects is one reason it is not used to treat regular flu. For a clinical trial that is under way in Japan, female patients will not be given it if they are pregnant.

Precautions

This drug is only approved as an experimental drug and still a lot of studies is needed about it’s efficacy and also toxic reactions and warning and precaution.

Overdose Effects

This drug is only approved as an experimental drug and still a lot of studies is needed about it’s efficacy and also toxic reactions.

Use in Special Population

This drug is only approved as an experimental drug and still a lot of studies is needed about it’s efficacy and also toxic reactions and use in children.

Storage Conditions

Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

Offer, Discount, Cashback & Many More

X